牛牛AI助理已提取核心訊息
Altamira Therapeutics Ltd., a biopharmaceutical company, has been informed by the United States Securities and Exchange Commission (SEC) that its registration statement on Form F-3, filed on January 8, 2024, will not undergo review. The SEC's communication, dated January 16, 2024, was addressed to Thomas Meyer, CEO of Altamira Therapeutics. The SEC's letter referenced Rules 460 and 461, which pertain to requests for acceleration of the registration process. Additionally, the SEC reminded the company and its management of their responsibility for the accuracy and adequacy of their disclosures, regardless of the SEC's level of review or lack thereof. For further inquiries, the SEC provided contact information for Tamika Sheppard.
Altamira Therapeutics Ltd., a biopharmaceutical company, has been informed by the United States Securities and Exchange Commission (SEC) that its registration statement on Form F-3, filed on January 8, 2024, will not undergo review. The SEC's communication, dated January 16, 2024, was addressed to Thomas Meyer, CEO of Altamira Therapeutics. The SEC's letter referenced Rules 460 and 461, which pertain to requests for acceleration of the registration process. Additionally, the SEC reminded the company and its management of their responsibility for the accuracy and adequacy of their disclosures, regardless of the SEC's level of review or lack thereof. For further inquiries, the SEC provided contact information for Tamika Sheppard.
美國證券交易委員會（SEC）已通知生物製藥公司Altamira Therapeutics Ltd.，其於2024年1月8日提交的F-3表格註冊聲明將不接受審查。美國證券交易委員會於2024年1月16日發給了Altamira Therapeutics首席執行官托馬斯·邁耶。美國證券交易委員會的信中引用了與加快註冊程序的請求有關的第460和461條。此外，美國證券交易委員會提醒該公司及其管理層，無論美國證券交易委員會的審查程度如何，他們都對披露的準確性和充分性負責。爲了進一步調查，美國證券交易委員會提供了塔米卡·謝潑德的聯繫信息。
美國證券交易委員會（SEC）已通知生物製藥公司Altamira Therapeutics Ltd.，其於2024年1月8日提交的F-3表格註冊聲明將不接受審查。美國證券交易委員會於2024年1月16日發給了Altamira Therapeutics首席執行官托馬斯·邁耶。美國證券交易委員會的信中引用了與加快註冊程序的請求有關的第460和461條。此外，美國證券交易委員會提醒該公司及其管理層，無論美國證券交易委員會的審查程度如何，他們都對披露的準確性和充分性負責。爲了進一步調查，美國證券交易委員會提供了塔米卡·謝潑德的聯繫信息。
有用
沒用